For those with EGFR wild-type NSCLC, the prognosis of non-DLM patients was no better than that of DLM patients (DLM vs. non-DLM: PFS: 3.5 vs. 3.4 months, p = 0.634; OS: 7.7 vs. 7.3 months, p = 0.521). This evidence concerns the gene EGFR and non-small cell lung carcinoma.